OOIR: Observatory of International Research

Papers

(The TQCC of Circulation is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Heart Disease and Stroke Statistics—2021 Update	3282
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association	2497
COVID-19 and Cardiovascular Disease	1228
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association	914
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association	855
Pulmonary Embolism in Patients With COVID-19	852
Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic	838
Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care	788
Cardiovascular Disease in Chronic Kidney Disease	676
The Science Underlying COVID-19	613
Myocarditis With COVID-19 mRNA Vaccines	599
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines	571
Obesity Is a Risk Factor for Severe COVID-19 Infection	539
Call to Action: Structural Racism as a Fundamental Driver of Health Disparities: A Presidential Advisory From the American Heart Association	534
Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association	525
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidel	501
Spectrum of Cardiac Manifestations in COVID-19	425
Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy	416
Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome	409
The Variety of Cardiovascular Presentations of COVID-19	396
Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association	390
Part 1: Executive Summary: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care	373
2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association	368
Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association	342
Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction	341

ST-Elevation Myocardial Infarction in Patients With COVID-19	331
2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines	327
Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association	322
Transcriptional and Cellular Diversity of the Human Heart	317
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clini	311
Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease	296
Deep Vein Thrombosis in Hospitalized Patients With COVID-19 in Wuhan, China	293
Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and Human	292
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque	281
Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association	267
Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation	258
Empagliflozin in Heart Failure	250
Interim Guidance for Basic and Advanced Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19	249
Psychological Health, Well-Being, and the Mind-Heart-Body Connection: A Scientific Statement From the American Heart Association	244
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus	236
Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy	228
Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association	227
Cardiorespiratory Fitness in Youth: An Important Marker of Health: A Scientific Statement From the American Heart Association	225
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)	225
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk	222
Acute Cardiovascular Manifestations in 286 Children With Multisystem Inflammatory Syndrome Associated With COVID-19 Infection in Europe	222
Stem Cell Pluripotency Genes Klf4 and Oct4 Regulate Complex SMC Phenotypic Changes Critical in Late-Stage Atherosclerotic Lesion Pathogenesis	221
Association of Body Mass Index and Age With Morbidity and Mortality in Patients Hospitalized With COVID-19	219
Part 4: Pediatric Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care	218
Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association	217
Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure	217
Will Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis?	215
Evidence-Based Assessment of Genes in Dilated Cardiomyopathy	214
Review of Cardiac Involvement in Multisystem Inflammatory Syndrome in Children	213
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction	210
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status	209
Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device	204
Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement From the American Heart Association	202
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association	196
Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990–2017	196
Angiotensin Converting Enzyme 2	193
Extracellular Vesicle–Mediated Delivery of Circular RNA SCMH1 Promotes Functional Recovery in Rodent and Nonhuman Primate Ischemic Stroke Models	190
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial	189
SARS-CoV-2 Cardiac Involvement in Young Competitive Athletes	189
COVID-19, Arrhythmic Risk, and Inflammation	189
Severe COVID-19 Is a Microvascular Disease	187
Colchicine in Patients With Acute Coronary Syndrome	186
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction	186
Microthrombi as a Major Cause of Cardiac Injury in COVID-19	185
Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial	184
Telemedicine Outpatient Cardiovascular Care During the COVID-19 Pandemic	181
Integrated Single-Cell Atlas of Endothelial Cells of the Human Lung	180
Self-Measured Blood Pressure Monitoring at Home: A Joint Policy Statement From the American Heart Association and American Medical Association	180
Fruit and Vegetable Intake and Mortality	179
Deficiency of Prebiotic Fiber and Insufficient Signaling Through Gut Metabolite-Sensing Receptors Leads to Cardiovascular Disease	173

Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction	171
Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies	171
Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients With Severe COVID-19 in Wuhan	169
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes	168
Neonatal Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations	166
Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Underlying Causes of Myocardial Infarction With Nonobstructive Coronary Arteries in Women	165
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function	164
Myocarditis After BNT162b2 and mRNA-1273 Vaccination	163
Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population	162
Myocarditis Temporally Associated With COVID-19 Vaccination	161
Part 5: Neonatal Resuscitation: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care	161
Lack of Evidence of Angiotensin-Converting Enzyme 2 Expression and Replicative Infection by SARS-CoV-2 in Human Endothelial Cells	161
Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction	159
Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease	153
Single-Cell RNA Sequencing Unveils Unique Transcriptomic Signatures of Organ-Specific Endothelial Cells	152
Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis	151
Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association	150
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Pr	150
High-Resolution Transcriptomic Profiling of the Heart During Chronic Stress Reveals Cellular Drivers of Cardiac Fibrosis and Hypertrophy	145
Pkm2 Regulates Cardiomyocyte Cell Cycle and Promotes Cardiac Regeneration	144
How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?	142
Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure	142
Single-Cell Transcriptome Analysis Reveals Dynamic Cell Populations and Differential Gene Expression Patterns in Control and Aneurysmal Human Aortic Tissue	141
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy	140
Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis	139
Diagnosis and Management of Myocarditis in Children	139
Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity	138
Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association	138
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy	137
High-Sensitivity Cardiac Troponin Can Be an Ally in the Fight Against COVID-19	137
COVID-19 Myocardial Pathology Evaluation in Athletes With Cardiac Magnetic Resonance (COMPETE CMR)	137
Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association	135
Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease	135
Deep Neural Networks Can Predict New-Onset Atrial Fibrillation From the 12-Lead ECG and Help Identify Those at Risk of Atrial Fibrillation–Related Stroke	134
Single-Cell RNA Sequencing Analysis Reveals a Crucial Role for CTHRC1 (Collagen Triple Helix Repeat Containing 1) Cardiac Fibroblasts After Myocardial Infarction	130
Unexpected Features of Cardiac Pathology in COVID-19 Infection	130
Cell-Free DNA to Detect Heart Allograft Acute Rejection	130
Fate and State of Vascular Smooth Muscle Cells in Atherosclerosis	130
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure	129
Blood Pressure Effects of Sodium Reduction	129
Single-Cell Reconstruction of Progression Trajectory Reveals Intervention Principles in Pathological Cardiac Hypertrophy	128
A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy	127
Evaluation and Management of Premature Ventricular Complexes	126
Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guideline	126
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines	125
Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: The AVATAR Trial	125
HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research	124
Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations	124
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease	123
Mechanical Complications of Acute Myocardial Infarction: A Scientific Statement From the American Heart Association	123
Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis	122
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF	122
Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination	121
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase	121
Value of Hemodynamic Monitoring in Patients With Cardiogenic Shock Undergoing Mechanical Circulatory Support	121
COVID-19–Associated Nonocclusive Fibrin Microthrombi in the Heart	120
Mortality and Paclitaxel-Coated Devices	120
COVID-19	120
Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction	120
Prevalence, Characteristics, and Outcomes of COVID-19–Associated Acute Myocarditis	119
Sex Differences in Blood Pressure Associations With Cardiovascular Outcomes	119
Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial	119
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Gui	119
Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment	118
Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial	117
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex	117
White Blood Cells and Blood Pressure	116
Differentiating COVID-19 Pneumonia From Acute Respiratory Distress Syndrome and High Altitude Pulmonary Edema	116
Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction	116
Status of Cardiovascular Health in US Adults and Children Using the American Heart Association’s New “Life’s Essential 8” Metrics: Prevalence Estimates From the National Health and Nutrition Examinati	116
Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure	115
Assessing and Addressing Cardiovascular Health in LGBTQ Adults: A Scientific Statement From the American Heart Association	115
Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease	115
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention	115
Therapeutic and Diagnostic Translation of Extracellular Vesicles in Cardiovascular Diseases	115
Association of COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in England and Wales	114
Ten-Year Differences in Women’s Awareness Related to Coronary Heart Disease: Results of the 2019 American Heart Association National Survey: A Special Report From the American Heart Association	114
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36	114
Fontan-Associated Liver Disease	113
Endotoxinemia Accelerates Atherosclerosis Through Electrostatic Charge–Mediated Monocyte Adhesion	113

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guide	113
Personal-Level Protective Actions Against Particulate Matter Air Pollution Exposure: A Scientific Statement From the American Heart Association	110
Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association	110
Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial	110
Hyperglycemia Induces Trained Immunity in Macrophages and Their Precursors and Promotes Atherosclerosis	109
Cardiovascular Risk of Isolated Systolic or Diastolic Hypertension in Young Adults	108
Circular RNA CircMAP3K5 Acts as a MicroRNA-22-3p Sponge to Promote Resolution of Intimal Hyperplasia Via TET2-Mediated Smooth Muscle Cell Differentiation	108
Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement From the American Heart Association	107
Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex	106
Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure])	106
Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy	106
Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure	106
Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction	105
Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents	105
Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin	105
Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019	105
US Mortality Attributable to Congenital Heart Disease Across the Lifespan From 1999 Through 2017 Exposes Persistent Racial/Ethnic Disparities	105
Altered Hemodynamics and End-Organ Damage in Heart Failure	103
Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries	103
Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19–Associated Coagulopathy	103
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial	103
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome	103
Racial and Ethnic Differences in Presentation and Outcomes for Patients Hospitalized With COVID-19: Findings From the American Heart Association’s COVID-19 Cardiovascular Disease Registry	102
Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association	102
Population Trends in Rates of Percutaneous Coronary Revascularization for Acute Coronary Syndromes Associated With the COVID-19 Outbreak	102
A Unique Population of Regulatory T Cells in Heart Potentiates Cardiac Protection From Myocardial Infarction	102
Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association	102
Assessing and Addressing Cardiovascular Health in People Who Are Transgender and Gender Diverse: A Scientific Statement From the American Heart Association	101
RIPK1 Expression Associates With Inflammation in Early Atherosclerosis in Humans and Can Be Therapeutically Silenced to Reduce NF-κB Activation and Atherogenesis in Mice	100
Invasive Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Scientific Statement From the American Heart Association	99
Extracellular Vesicles From Epicardial Fat Facilitate Atrial Fibrillation	99
Increasing Fatty Acid Oxidation Prevents High-Fat Diet–Induced Cardiomyopathy Through Regulating Parkin-Mediated Mitophagy	98
Pathogenic Autoimmunity in Atherosclerosis Evolves From Initially Protective Apolipoprotein B ₁₀₀ –Reactive CD4 ⁺ T-Regulatory Cel	98
ECG-Based Deep Learning and Clinical Risk Factors to Predict Atrial Fibrillation	98
Randomized Pilot Clinical Trial of Early Coronary Angiography Versus No Early Coronary Angiography After Cardiac Arrest Without ST-Segment Elevation	97
Cardiovascular Health in American Indians and Alaska Natives: A Scientific Statement From the American Heart Association	97
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials	96
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary	96
Myocardial Injury in Severe COVID-19 Compared With Non–COVID-19 Acute Respiratory Distress Syndrome	96
Bariatric Surgery and Cardiovascular Outcomes in Patients With Obesity and Cardiovascular Disease:	95
Comparison of Self-Expanding Bioprostheses for Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis	94
Takotsubo Syndrome: Pathophysiology, Emerging Concepts, and Clinical Implications	93
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease	93
Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension	92
Guidance for Timely and Appropriate Referral of Patients With Advanced Heart Failure: A Scientific Statement From the American Heart Association	92
Transcatheter Aortic Valve Replacement in Bicuspid Aortic Valve Stenosis	92
Cardiometabolic Traits, Sepsis, and Severe COVID-19	91
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Cli	91
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y ₁₂ Inhibitor in Patients After Percutaneous Coronary Intervention	91
Altered Cardiac Energetics and Mitochondrial Dysfunction in Hypertrophic Cardiomyopathy	90
In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine	90
Diagnosis and Management of Patients With Myocardial Injury After Noncardiac Surgery: A Scientific Statement From the American Heart Association	90
Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electroc	90
Rise in Blood Pressure Observed Among US Adults During the COVID-19 Pandemic	88
Part 7: Systems of Care: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care	87
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER	86
Comprehensive Evaluation of Rhythm Monitoring Strategies in Screening for Atrial Fibrillation	86
Heart Regeneration by Endogenous Stem Cells and Cardiomyocyte Proliferation	86
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial	86
Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement	86
Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women	86
Single-Cell RNA Sequencing to Dissect the Immunological Network of Autoimmune Myocarditis	86
Incidence, Microbiology, and Outcomes in Patients Hospitalized With Infective Endocarditis	86
Comparative Efficacy and Safety of Oral P2Y ₁₂ Inhibitors in Acute Coronary Syndrome	85
Part 6: Resuscitation Education Science: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care	85
gp130 Controls Cardiomyocyte Proliferation and Heart Regeneration	84
Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients	84
Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70	84
An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction	84
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease	84
The COMPASS Trial	83
Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19	82
CSC Expert Consensus on Principles of Clinical Management of Patients With Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic	82
Red Blood Cell and Endothelial eNOS Independently Regulate Circulating Nitric Oxide Metabolites and Blood Pressure	82
Myocardial Infarction in the ISCHEMIA Trial	81
Neutrophils and Contact Activation of Coagulation as Potential Drivers of COVID-19	81
Long Noncoding RNA MIAT Controls Advanced Atherosclerotic Lesion Formation and Plaque Destabilization	81
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease	81
High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled Trial	81
Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial	81
Replacement Myocardial Fibrosis in Patients With Mitral Valve Prolapse	81
Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome	80
General Versus Local Anesthesia With Conscious Sedation in Transcatheter Aortic Valve Implantation	80
Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis	80
Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study	80
Exercise and Coronary Atherosclerosis	80
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention	80
Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease	79
At the Heart of the Matter	79
Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction	79
Adult Basic Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations	78
Coronary Artery Anomalies	78
Prevalence of Infective Endocarditis in Streptococcal Bloodstream Infections Is Dependent on Streptococcal Species	77
Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin	77
A Novel Endocrine Role for the BAT-Released Lipokine 12,13-diHOME to Mediate Cardiac Function	76